REG - Burning Rock Biotech - Published in the New England Journal of Medicine

Burning Rock BiotechAnnouncement

08/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230608:nRSH0855Ca&default-theme=true

RNS Number : 0855C  Burning Rock Biotech Limited  08 June 2023

Burning Rock's precision oncology diagnostics product supports advancement in
late-stage breast cancer treatment, with results published in the New England
Journal of Medicine

 

 

GUANGZHOU, China, June 8, 2023 (GLOBE NEWSWIRE) -Burning Rock Biotech Limited
(NASDAQ: BNR and LSE: BNR, the "Company" or "Burning Rock") is pleased to
announce that our flagship comprehensive genomic profiling (CGP) product,
OncoScreen(TM) Plus, was featured in a phase 3 multi-regional clinical trial
(MRCT), along with FoundationOneCDx, in support of advancement in breast
cancer treatment.

 

The study, CAPItello-291, sponsored by our pharma client AstraZeneca, is a
phase 3 trial that assessed the efficacy and safety of
Capivasertib-fulvestrant therapy in advanced breast cancer patients with
hormone receptor positive (HR+), human epidermal growth factor receptor 2
negative (HER2-) cancer whose disease had progressed during or after aromatase
inhibitor therapy. The study demonstrated that Capivasertib-fulvestrant
combination therapy resulted in significantly longer progression-free survival
than treatment with fulvestrant alone.

 

In the study, Burning Rock's flagship comprehensive genomic profiling (CGP)
product, OncoScreen(TM) Plus, was used to determine activating mutations in
PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients
enrolled in China. We are proud to have supported our pharma client in such a
high impact study, after a rigorous test solution provider evaluation process.

 

 

Reference

 1  Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N ENGL J
MED 388. June, 2023

https://www.nejm.org/doi/full/10.1056/NEJMoa2214131

 

 

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to
guard life via science, focuses on the application of next generation
sequencing (NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage cancer
patients, and ii) cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.

 

For more information about Burning Rock, please visit: www.brbiotech.com.

 

Enquiries:

Contact: IR@brbiotech.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESUPURGQUPWUCR